When midazolam fails

被引:39
作者
Cheng, C
Roemer-Becuwe, C
Pereira, J
机构
[1] Grey Nuns Community Hosp, Palliat Care Program, Edmonton, AB, Canada
[2] Univ Calgary, Div Palliat Med, Calgary, AB, Canada
[3] Foothills Prov Gen Hosp, Tertiary Palliat Care Unit, Calgary, AB T2N 2T9, Canada
关键词
palliative; sedation; midazolam; propofol; phenobarbital;
D O I
10.1016/S0885-3924(01)00412-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Significant distress is experienced by patients, families, and caregivers when a symptom or disorder such as an agitated delirium, becomes all intractable, or a catastrophic event. such as irreversible stridor When. palliative sedation is indicated for these patients, midazolam is usually the preferred drug. In some cases, however midazolam fails to provide adequate sedation. Two cases are presented to illustrate this phenomenon and explore the possible mechanisms underlying this lack response. These mechanisms appear to be multifaceted. The heterogeneity of the GABA(A) receptor complex rind the alterations that this complex can undergo functionally can explain, to some degree, the diversity of the physiological and pharmacological outcomes. Other factors responsible for the diversity in response may include concomitant medications, age, concurrent disease, overall health status, alcohol use, liver disease, renal disease, smoking and hormonal status. Evidence-based guidelines on alternative treatment options should midazolam fail are required. In the interim, a lower threshold for adding an alternative drug, such as phenobarbital, or substituting midazolam with another drug, such as propofol, should be considered in these circumstances. J Pain Symptom Manage 2002;23:256-265. (C) US. Cancer Pain Relief Committee, 2002.
引用
收藏
页码:256 / 265
页数:10
相关论文
共 59 条
[1]   ETHANOL POTENTIATES THE GABA-A-ACTIVATED CL- CURRENT IN MOUSE HIPPOCAMPAL AND CORTICAL-NEURONS [J].
AGUAYO, LG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 187 (01) :127-130
[2]   MIDAZOLAM KINETICS [J].
ALLONEN, H ;
ZIEGLER, G ;
KLOTZ, U .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (05) :653-661
[3]   Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam [J].
Bauer, LO ;
Gross, JB ;
Meyer, RE ;
Greenblatt, DJ .
PSYCHOPHARMACOLOGY, 1997, 133 (03) :293-299
[4]   Drug interactions in palliative care [J].
Bernard, SA ;
Bruera, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1780-1799
[5]   Clinical pharmacology of midazolam in infants and children [J].
Blumer, JL .
CLINICAL PHARMACOKINETICS, 1998, 35 (01) :37-47
[6]   SUBHYPNOTIC DOSES OF PROPOFOL RELIEVE PRURITUS ASSOCIATED WITH LIVER-DISEASE [J].
BORGEAT, A ;
WILDERSMITH, OHG ;
MENTHA, G .
GASTROENTEROLOGY, 1993, 104 (01) :244-247
[7]  
Bottomley D M, 1990, J Pain Symptom Manage, V5, P259, DOI 10.1016/0885-3924(90)90020-K
[8]  
BOURNE HR, 1995, BASIC CLIN PHARM, P9
[9]   TERMINAL RESTLESSNESS - ITS MANAGEMENT AND THE ROLE OF MIDAZOLAM [J].
BURKE, AL ;
DIAMOND, PL ;
HULBERT, J ;
YEATMAN, J ;
FARR, EA .
MEDICAL JOURNAL OF AUSTRALIA, 1991, 155 (07) :485-487
[10]   ACCUMULATION OF MIDAZOLAM AFTER REPEATED DOSAGE IN PATIENTS RECEIVING MECHANICAL VENTILATION IN AN INTENSIVE-CARE UNIT [J].
BYATT, CM ;
LEWIS, LD ;
DAWLING, S ;
COCHRANE, GM .
BRITISH MEDICAL JOURNAL, 1984, 289 (6448) :799-800